Once-daily tofacitinib formulation gets FDA clearance for RA

The Food and Drug Administration has approved a once-daily, extended-release tablet formulation of tofacitinib 11 mg, the drug’s manufacturer, Pfizer, announced. The Janus kinase inhibitor, to be...
Source: Rheumatology News - Category: Rheumatology Source Type: research